Heron Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Heron Therapeutics CEO'su Craig Collard, Apr2023 tarihinde atandı, in görev süresi 1.75 yıldır. şirketin hisselerinin 0.18% doğrudan sahiptir ve bu hisselerin değeri $ 442.74K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.6 yıl ve 3.3 yıldır.

Anahtar bilgiler

Craig Collard

İcra Kurulu Başkanı

US$5.5k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.8yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	1.6yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Craig Collard (58 yo)

1.8yrs

Görev süresi

US$5,486

Tazminat

Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Collard	CEO & Director	1.8yrs	US$5.49k	0.18% $ 442.7k
Ira Duarte	Executive VP & CFO	1.6yrs	US$1.76m	0.071% $ 179.3k
William Forbes	Executive VP & Chief Development Officer	1.6yrs	US$1.71m	0.068% $ 171.2k
Ryan Craig	Vice President of Marketing	1.4yrs	Veri yok	Veri yok
Sean Ristine	Senior Vice President of Human Resources	9.3yrs	Veri yok	Veri yok
Robert Sullivan	Senior Vice President of Oncology Care Franchise & Commercial Operations	2yrs	Veri yok	Veri yok
Brett Fleshman	Chief Business Officer	less than a year	Veri yok	Veri yok
Jeff Cohn	Executive Director	no data	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 0J4V 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.6 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Craig Collard	CEO & Director	1.9yrs	US$5.49k	0.18% $ 442.7k
Craig Johnson	Independent Director	11yrs	US$11.02m	0.034% $ 86.1k
Christian Waage	Independent Director	8.6yrs	US$70.51k	0.034% $ 86.7k
Michael Kaseta	Director	less than a year	Veri yok	Veri yok
Susan Rodriguez	Independent Director	3.3yrs	US$65.63k	0.035% $ 87.9k
Adam Morgan	Independent Chairman	1.9yrs	US$545.53k	0.0062% $ 15.7k
Sharmila Dissanaike	Independent Director	3.3yrs	US$55.00k	0.035% $ 87.9k

3.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0J4V 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/05 14:28
Gün Sonu Hisse Fiyatı	2025/01/03 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Heron Therapeutics, Inc. 18 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Jonathan Aschoff	Brean Capital
Jonathan Aschoff	B. Riley Wealth

Heron Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Heron Therapeutics, Inc. Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought US$138k worth of stock

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Recent updates

Forecast breakeven date pushed back to 2026

Third quarter 2024 earnings released: US$0.032 loss per share (vs US$0.17 loss in 3Q 2023)

Heron Therapeutics, Inc. Revises Earnings Guidance for the Year 2024

Forecast breakeven date pushed back to 2026

Heron Therapeutics, Inc. Announces Appointment of Michael Kaseta to Board of Directors

Heron Therapeutics, Inc. Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: US$0.061 loss per share (vs US$0.35 loss in 2Q 2023)

Heron Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle

Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings released: US$0.021 loss per share (vs US$0.28 loss in 1Q 2023)

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$0.80 loss per share (vs US$1.67 loss in FY 2022)

Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Forecast to breakeven in 2026

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought US$138k worth of stock

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.38 loss in 3Q 2022)

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.35 loss per share (vs US$0.55 loss in 2Q 2022)

Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Heron Therapeutics, Inc. Announces Management Changes

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.63 loss in 1Q 2022)

Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings released: US$1.67 loss per share (vs US$2.24 loss in FY 2021)

High number of new directors

Rubric Capital Management Engages with Heron Therapeutics

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF

Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022

Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting

Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.62 loss in 2Q 2021)

Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022

Heron Therapeutics, Inc. Does Not Provide Financial Guidance for the Full Year 2022

Heron Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Forecast to breakeven in 2024

Heron Therapeutics, Inc. Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.64 loss in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.62 loss per share (vs US$0.61 loss in 2Q 2020)

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF for the Management of Postoperative Pain for up to 72 Hours

Heron Therapeutics, Inc. announced that it expects to receive $150 million in funding from Baker Bros. Advisors LP

Heron Therapeutics Receives Approval from U.S. Food and Drug Administration for ZYNRELEF

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2021

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.57 loss in 1Q 2020)